An LMP1 peptide epitope was fused to a Tobacco Mosaic virus (TMV) carrier, to improve immunogenicity by increasing peptide uptake and activation by antigen-presenting cells [29,30,31], with the goal to improve survival above that observed in the original Delbende experiments, where survival was improved, but all mice died from the tumor challenge [25]. The gene discussed is PDLIM7; the disease is neoplasm.